SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on October 26, 2009, reporting events that occurred on October 23, 2009. The filing details the closing of a previously announced equity financing transaction.
Key Financial Metrics
- Gross Proceeds: $5 million in cash.
- Shares Issued: 6,072,383 shares of common stock.
- Price Per Share: $0.8234.
- Warrants Issued to Investors: 2,125,334 warrants with an exercise price of $1.00 per share.
- Placement Agent Warrants: 245,932 warrants with an exercise price of $1.029 per share issued to Rodman & Renshaw, LLC.
- Total Shares Outstanding: 71,924,496 shares following the offering.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in share count and capitalization resulting from the closing of the $5 million offering. The transaction was executed with five institutional investors.
Outlook and Management Commentary
Management confirmed the closing of the transaction as contemplated by the Securities Purchase Agreement. A press release dated October 26, 2009, is attached as Exhibit 99.1 and incorporated by reference. The filing does not contain specific forward-looking guidance, risk factors, or discussion of unusual items beyond the financing event.
Investor Verification Checklist
- Verify the final number of shares outstanding (71,924,496) against subsequent filings.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Confirm the terms of the warrants issued to institutional investors and the placement agent.
- Check for any dilution impact on existing shareholders given the issuance of over 6 million new shares.